PALMERI, Laura
 Distribuzione geografica
Continente #
NA - Nord America 1.282
EU - Europa 635
AS - Asia 209
AF - Africa 12
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.141
Nazione #
US - Stati Uniti d'America 1.280
IT - Italia 147
CN - Cina 140
FI - Finlandia 132
UA - Ucraina 126
DE - Germania 88
SG - Singapore 49
GB - Regno Unito 34
IE - Irlanda 29
BE - Belgio 18
RO - Romania 18
SE - Svezia 14
IN - India 13
RU - Federazione Russa 13
CI - Costa d'Avorio 12
FR - Francia 7
ES - Italia 4
IR - Iran 4
CA - Canada 2
CL - Cile 2
NL - Olanda 2
AT - Austria 1
EU - Europa 1
GR - Grecia 1
HK - Hong Kong 1
ID - Indonesia 1
KR - Corea 1
LT - Lituania 1
Totale 2.141
Città #
Fairfield 154
Ashburn 137
Chandler 125
Woodbridge 117
Ann Arbor 101
Jacksonville 72
Houston 68
Wilmington 68
Des Moines 59
Seattle 53
Cambridge 51
Palermo 36
Singapore 34
Medford 31
Dublin 29
Nanjing 26
Altamura 21
Princeton 19
Brussels 18
Beijing 16
Boardman 15
Lawrence 14
Tulsa 13
Abidjan 12
Dearborn 12
Jinan 12
Nanchang 12
Changsha 11
Washington 11
Jiaxing 10
Shenyang 10
Kumar 9
San Diego 8
Tianjin 8
Hebei 7
New York 7
Zhengzhou 6
Ludwigshafen am Rhein 5
Verona 5
Albacete 4
Cagliari 4
Falls Church 4
Santa Clara 4
Tehran 4
Helsinki 3
Ningbo 3
Norwalk 3
Rome 3
San Paolo di Civitate 3
Hangzhou 2
Kilburn 2
Kunming 2
Lanzhou 2
London 2
Phoenix 2
San Mateo 2
Taizhou 2
Torino 2
Venice 2
Auburn Hills 1
Bremen 1
Bristol 1
Central District 1
Chicago 1
Columbus 1
Costa Mesa 1
Council Bluffs 1
Dallas 1
Durham 1
Fuzhou 1
Guangzhou 1
Haikou 1
Hanover 1
Hefei 1
Hyderabad 1
Kitzingen 1
Lecce 1
Levanto 1
Milan 1
Nanning 1
Orange 1
Ottawa 1
Piscataway 1
Prescot 1
Pune 1
Saint Petersburg 1
Santiago 1
Seongnam 1
Shanghai 1
Shaoxing 1
Taiyuan 1
Toronto 1
Wageningen 1
Totale 1.511
Nome #
Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. 205
“Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma” 174
“Cytokine gene polymorphisms and breast cancer susceptibility” 155
“Weekly docetaxel and gemcitabine as first line treatment for metastatic breast cancer: results of a multicenter phase II study” 154
"Weekly docetaxel in the treatment of metastatic breast cancer" 151
Improved resolution power of electrophoretic fractionation of DNA using a voltage gradient up and down application 137
“Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site” 126
“High efficacy of the CHOP + Rituximab association in a case of primary rectal non Hodgkin lymphoma (NHL)” 123
"Should cirrhosis change our attitude towards treating non-hepatic cancer?" 116
Prognostic value of vascular endothelial growth factor (VEGF) and D-Dimer (DD) levels in cancer patients 113
“Serum HER-2/neu (s-HER2) levels evaluation in breast cancer (BC) patients (PTS)” 105
“Evaluating the prognostic role of serum extracellular domain (ECD) of HER-2/neu (s-HER2) in patients (PTS) with metastatic (M) breast cancer (BC): results of an observational study” 100
Weekly docetaxel (wDOC) for the treatment of metastatic breast cancer (MBC): A literature based meta-analysis 96
"Evaluating the prognostic role of serum extracellular domain (ECD) of HER-2/neu (s-HER2) in patients (PTS) with early (E) breast cancer (BC)” 85
“Final results of a phase II trial of a weekly (W) poly-chemotherapy (CT) with cisplatin (CDDP), epirubicin (EPI), fluorouracil (5FU), folinic acid (FA) and G-CSF for the treatment of gastroesophageal (GE) and gastric (G) cancer (C)” 74
“Role of loco-regional treatments for patients with breast cancer liver metastases” 72
GASTRIC CANCER (GC) ADJUVANT (A) CHEMOTHERAPY (CT): A LITERATURE BASED META-ANALYSIS (MA) 69
“Results of a phase II study of a weekly regimen of cisplatin (CDDP),epirubicin (EPI), fluorouracil (5FU) and folinic acid (FA) with G-CSF in gastroesophageal (GE) and gastric (G) cancer” 68
CISPLATIN (C) AND ALIMTA (A) WITH PANITUMUMAB FOR ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NS-NSCLC): A PHASE I-DOSE FINDING STUDY. 43
Totale 2.166
Categoria #
all - tutte 7.395
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.395


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020316 0 0 0 0 0 57 51 31 56 24 67 30
2020/2021238 8 27 7 25 33 5 21 10 41 16 24 21
2021/2022203 10 56 1 5 9 9 12 10 28 15 7 41
2022/2023355 42 61 6 30 43 59 48 23 28 1 4 10
2023/2024171 11 17 6 30 23 32 11 23 0 0 0 18
2024/202578 3 7 21 37 8 2 0 0 0 0 0 0
Totale 2.166